Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL

Enrollment

592

Participants

Timeline

Start Date

November 28, 2007

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Ulcerative Colitis

Interventions

BIOLOGICAL

adalimumab

adalimumab prefilled syringes administered as subcutaneous injection EW or EOW

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00573794 - Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis | Biotech Hunter | Biotech Hunter